Citations (17)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Kaida Jiang, Lingjiang Li, Xueyi Wang, Maosheng Fang, Jianfei Shi, Qiuyun Cao, Jincai He, Jinan Wang, Weihao Tan & Cuili Hu. (2017) Efficacy and tolerability of escitalopram in treatment of major depressive disorder with anxiety symptoms: a 24-week, open-label, prospective study in Chinese population. Neuropsychiatric Disease and Treatment 13, pages 515-526.
Read now
Read now
Borwin Bandelow, Michael Bauer, Eduard Vieta, Nizar El-Khalili, Urban Gustafsson, Willie R. Earley & Hans Eriksson. (2014) Extended release quetiapine fumarate as adjunct to antidepressant therapy in patients with major depressive disorder: pooled analyses of data in patients with anxious depression versus low levels of anxiety at baseline. The World Journal of Biological Psychiatry 15:2, pages 155-166.
Read now
Read now
Articles from other publishers (15)
Kristin Köhler-Forsberg, Brice Ozenne, Søren V. Larsen, Asbjørn S. Poulsen, Elizabeth B. Landman, Vibeke H. Dam, Cheng-Teng Ip, Anders Jørgensen, Claus Svarer, Gitte M. Knudsen, Vibe G. Frokjaer & Martin B. Jørgensen. (2022) Concurrent anxiety in patients with major depression and cerebral serotonin 4 receptor binding. A NeuroPharm-1 study. Translational Psychiatry 12:1.
Crossref
Crossref
Caroline W. Espinola, Yuelee Khoo, Roohie Parmar, Ilya Demchenko, Benicio N. Frey, Roumen V. Milev, Arun V. Ravindran, Sagar V. Parikh, Keith Ho, Susan Rotzinger, Wendy Lou, Raymond W. Lam, Sidney H. Kennedy & Venkat Bhat. (2022) Pretreatment anxious depression as a predictor of side effect frequency and severity in escitalopram and aripiprazole adjunctive therapy. Brain and Behavior 12:5.
Crossref
Crossref
Thalia Richter, Barak Fishbain, Andrey Markus, Gal Richter-Levin & Hadas Okon-Singer. (2020) Using machine learning-based analysis for behavioral differentiation between anxiety and depression. Scientific Reports 10:1.
Crossref
Crossref
Ji-hua Xu & Peng Jiang. (2018) Efficacy of escitalopram oxalate for patients with post-stroke depression. Medicine 97:14, pages e0219.
Crossref
Crossref
Jingyu Lin, Yunai Su, Chunxia Wang, Fude Yang, Yi Xu, Yonggui Yuan, Yefeng Yuan, Xiaoping Wang, Xin Yu & Tianmei Si. (2018) Effects of tandospirone augmentation in major depressive disorder patients with high anxiety: A multicenter, randomized, parallel-controlled, open-label study. Journal of Psychiatric Research 99, pages 104-110.
Crossref
Crossref
Wei-Hong Kuang, Zai-Quan Dong, Lian-Tian Tian & Jin Li. (2018) MicroRNA-451a, microRNA-34a-5p, and microRNA-221-3p as predictors of response to antidepressant treatment. Brazilian Journal of Medical and Biological Research 51:7.
Crossref
Crossref
Guanjun Li, Yifeng Shen, Jianfeng Luo & Huafang Li. (2017) Efficacy of escitalopram monotherapy in the treatment of major depressive disorder. Medicine 96:39, pages e8142.
Crossref
Crossref
David S. Baldwin, Ioana Florea, Paula L. Jacobsen, Wei Zhong & George G. Nomikos. (2016) A meta-analysis of the efficacy of vortioxetine in patients with major depressive disorder (MDD) and high levels of anxiety symptoms. Journal of Affective Disorders 206, pages 140-150.
Crossref
Crossref
Shinichiro Nakajima, Hitoshi Tanimukai, Mika Baba, Koji Amano, Muneyoshi Kawasaki & Hiroshi Wakayama. (2013) Two advanced cancer patients in whom escitalopram was useful for depression. Palliative Care Research 8:2, pages 548-553.
Crossref
Crossref
Klaus P. Bøgesø & Connie Sánchez. 2012. Analogue‐Based Drug Discovery III. Analogue‐Based Drug Discovery III
269
294
.
Andrea Cipriani, Marianna Purgato, Toshi A Furukawa, Carlotta Trespidi, Giuseppe Imperadore, Alessandra Signoretti, Rachel Churchill, Norio Watanabe & Corrado Barbui. (2012) Citalopram versus other anti-depressive agents for depression. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Kylie J. Thaler, Laura C. Morgan, Megan Van Noord, Bradley N. Gaynes, Richard A. Hansen, Linda J. Lux, Erin E. Krebs, Kathleen N. Lohr & Gerald Gartlehner. (2012) COMPARATIVE EFFECTIVENESS OF SECOND-GENERATION ANTIDEPRESSANTS FOR ACCOMPANYING ANXIETY, INSOMNIA, AND PAIN IN DEPRESSED PATIENTS: A SYSTEMATIC REVIEW. Depression and Anxiety 29:6, pages 495-505.
Crossref
Crossref
. (2011) Current World Literature. Current Opinion in Psychiatry 24:1, pages 78-87.
Crossref
Crossref
Elisabeth Dow, Valerie Piet, Adam Stewart, Siddharth Gaikwad, Jonathan Cachat, Peter Hart, Nadine Wu, Evan Kyzar, Eli Utterback, Alan Newman, Molly Hook, Kathryn Rhymes, Dillon Carlos & Allan V. Kalueff. 2011. Mood and Anxiety Related Phenotypes in Mice. Mood and Anxiety Related Phenotypes in Mice
61
81
.
J.-C. Chauvet-Gélinier. (2010) Efficacité de l’escitalopram vs paroxétine sur les formes de dépressions sévères avec symptômes anxieux associés. Données issues de l’étude « Boulenger » : escitalopram versus paroxétine. L'Encéphale 36:5, pages 425-432.
Crossref
Crossref